Bionomics, a leading Australian central nervous system (CNS) and cancer biotechnology company, and PerkinElmer, Inc. a leading provider of drug discovery, life science research and analytical solutions, today announced that they had reached an agreement to collaborate on GPCR and Ion Channel Technologies.
This collaboration recognizes the value of Bionomics’ ionX® program for the discovery and development of ion channel drugs for CNS disorders, specifically epilepsy and anxiety. Under this agreement, Bionomics and PerkinElmer will collaborate in the evaluation and optimization of new ion channel reagents.
Bionomics will also incorporate the ImageTrak, PerkinElmer’s kinetic cellular screening platform, into Bionomics’ CNS drug discovery programs. In addition Bionomics will serve as a reference site for PerkinElmer’s cellular screening platforms in the Asian market. PerkinElmer’s ImageTrak is a versatile cellular imaging platform utilizing patented fiber-optic imaging and fully integrated liquid handling. It is well suited for automated high-throughput screening against ion channels and GPCRs in lead discovery, using both standard probes as well as novel, highly sensitive ratiometric probes.
“We are pleased to collaborate with PerkinElmer for cellular screening in the Asian market and that PerkinElmer, a leader in drug discovery technologies, has recognized Bionomics’ expertise and the value of our ionX® platform. We look forward to incorporating PerkinElmer’s technologies in our drug discovery program for epilepsy and anxiety,” said Dr Deborah Rathjen, CEO & Managing Director for Bionomics.
“Bionomics clearly understands the value of high-throughput live cell imaging and its impact on future drug discovery. We look forward to further building our relationship with Bionomics and enabling them to develop the best fluorescent screening technologies available for ion channel targeted drug discovery,” said Peter Coggins, president, PerkinElmer Life and Analytical Sciences.